These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma. Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769 [TBL] [Abstract][Full Text] [Related]
3. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381 [TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis. Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088 [TBL] [Abstract][Full Text] [Related]
5. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization. Pedot G; Marques JG; Ambühl PP; Wachtel M; Kasper S; Ngo QA; Niggli FK; Schäfer BW Neoplasia; 2022 May; 27():100784. PubMed ID: 35366465 [TBL] [Abstract][Full Text] [Related]
7. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942 [TBL] [Abstract][Full Text] [Related]
8. Fusion protein EWS-FLI1 is incorporated into a protein granule in cells. Ahmed NS; Harrell LM; Wieland DR; Lay MA; Thompson VF; Schwartz JC RNA; 2021 May; 27(8):920-32. PubMed ID: 34035145 [TBL] [Abstract][Full Text] [Related]
12. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Herrero-Martín D; Osuna D; Ordóñez JL; Sevillano V; Martins AS; Mackintosh C; Campos M; Madoz-Gúrpide J; Otero-Motta AP; Caballero G; Amaral AT; Wai DH; Braun Y; Eisenacher M; Schaefer KL; Poremba C; de Alava E Br J Cancer; 2009 Jul; 101(1):80-90. PubMed ID: 19491900 [TBL] [Abstract][Full Text] [Related]
13. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296 [TBL] [Abstract][Full Text] [Related]
14. Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma. Dallmayer M; Li J; Ohmura S; Alba Rubio R; Baldauf MC; Hölting TLB; Musa J; Knott MML; Stein S; Cidre-Aranaz F; Wehweck FS; Romero-Pérez L; Gerke JS; Orth MF; Marchetto A; Kirchner T; Bach H; Sannino G; Grünewald TGP Cell Death Dis; 2019 Feb; 10(2):116. PubMed ID: 30741933 [TBL] [Abstract][Full Text] [Related]
15. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma. Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex. Mo J; Tan K; Dong Y; Lu W; Liu F; Mei Y; Huang H; Zhao K; Lv Z; Ye Y; Tang Y Oncogene; 2023 Jan; 42(1):11-25. PubMed ID: 36357572 [TBL] [Abstract][Full Text] [Related]
17. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472 [TBL] [Abstract][Full Text] [Related]
18. SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth. Su S; Chen J; Jiang Y; Wang Y; Vital T; Zhang J; Laggner C; Nguyen KT; Zhu Z; Prevatte AW; Barker NK; Herring LE; Davis IJ; Liu P Adv Sci (Weinh); 2021 Jul; 8(14):e2004846. PubMed ID: 34060252 [TBL] [Abstract][Full Text] [Related]
19. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue. Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic and Transcriptional Signaling in Ewing Sarcoma-Disease Etiology and Therapeutic Opportunities. Li M; Chen CW Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]